Hope Rugo

Oct 11, 2024 | onclive.com | Hope Rugo

Hope S.

Oct 2, 2024 | onclive.com | Hope Rugo |Aditya Bardia

OpinionVideoOctober 2, 2024Author(s):Panelists discuss how addressing unmet needs in patient selection, resistance mechanisms, and long-term outcomes can enhance the efficacy of antibody-drug conjugates in breast cancer treatment.

Oct 2, 2024 | digitalcommons.library.tmc.edu | Jennifer K. Litton |Meredith M. Regan |Lajos Pusztai |Hope Rugo

PURPOSE: The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to separately address end points for neoadjuvant clinical trials. The multidisciplinary NeoSTEEP working group of experts was convened to critically evaluate and align neoadjuvant BC trial end points.

Sep 25, 2024 | onclive.com | Hope Rugo |Aditya Bardia

OpinionVideoSeptember 25, 2024Author(s):Panelists discuss how, despite the investigational status of agents like patritumab deruxtecan (HER3-DXd) and datopotamab deruxtecan (Dato-DXd), it’s crucial for community oncologists to be aware of the treatment-related adverse effects (TRAEs) associated with these therapies and to consider effective management strategies as reported in clinical trials.

Sep 24, 2024 | onclive.com | Hope Rugo |Aditya Bardia

OpinionVideoSeptember 24, 2024Author(s):Panelists discuss how ongoing clinical trials of investigational antibody-drug conjugates (ADCs) are advancing treatment options for breast cancer, particularly in patients with active brain metastases and advanced disease. Video content above is prompted by the following:Please review some ongoing clinical trials and studies utilizing investigational ADCs in breast cancer that are in progress that may be interesting. (See below for a few suggestions.